Tempest Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Tempest Therapeutics, Inc. (TPST) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 0.95% for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2021-05-13
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2021-03-31 was 0.95%, a 30.15% decline year-over-year.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2020-09-30 was 0.36%, a 76.16% decline year-over-year.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2020-06-30 was 0.43%, a 77.49% decline year-over-year.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2020-03-31 was 1.36%, a 46.67% decline year-over-year.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2020 was 0.86%, a 61.26% decline from fiscal 2019.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2019 was 2.22%, a 19.86% decline from fiscal 2018.
- Tempest Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2018 was 2.77%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2021-03-31 | 0.95% 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | 0.86% 10-K · filed 2021-03-29 | |||
| 2020-09-30 | 0.36% 10-Q · filed 2020-11-09 | 0.87% 10-Q · filed 2020-11-09 | ||
| 2020-06-30 | 0.43% 10-Q · filed 2020-08-10 | 0.87% 10-Q · filed 2020-08-10 | ||
| 2020-03-31 | 1.36% 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | 2.22% 10-K · filed 2021-03-29 | |||
| 2019-09-30 | 1.51% 10-Q · filed 2020-11-09 | 2.23% 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | 1.91% 10-Q · filed 2020-08-10 | 2.35% 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | 2.55% 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | 2.77% 10-K · filed 2020-03-11 | |||
| 2018-09-30 | 2.78% 10-Q · filed 2019-11-13 | 2.78% 10-Q · filed 2019-11-13 | ||
| 2018-03-31 | 2.70% 10-Q · filed 2018-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |